Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPORTANT trial
2023-506620-87-00Phase 4Authorised
- Sponsor
- Region Örebro län
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 4, randomised, open-label trial of palbociclib, ribociclib and abemaciclib in breast cancer (2 arms), sponsored by Region Örebro län. Primary endpoint: Time to treatment failure. Planned start Nov 2023; status: authorised.
02
Drugs
palbociclibribociclibabemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-506620-87-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506620-87-00.